NASDAQ (usa) arrow 6715.56 -12.11 -0.18%
FTSE 100 (london) arrow 7487.96 -5.12 -0.07%
DAX (german) arrow 13465.51 235.94 1.78%
NIKKEI 225 (japan) arrow 22420.08 408.47 1.86%
Hang - Seng (hong kong) arrow 28594.06 348.52 1.23%
NIFTY - 50 (india)
Straits Times (singapore) arrow 3391.61 17.53 0.52%
KOSPI (korea) arrow 2556.47 33.04 1.31%
All Ordinaries (australia) arrow 6005.30 28.90 0.48%
BOVESPA (brazil) arrow 74092.76 -215.73 -0.29%

Xbrane Biopharma AB (publ) (ST: XBRANE)

 
XBRANE Technical Analysis
5
As on 22nd Nov 2024 XBRANE STOCK Price closed @ 0.19 and we RECOMMEND Strong Sell for LONG-TERM with Stoploss of 24.86 & Strong Sell for SHORT-TERM with Stoploss of 71.51 we also expect STOCK to react on Following IMPORTANT LEVELS.
 
 

XBRANESTOCK Price

Open 0.20 Change Price %
High 0.20 1 Day -0.01 -5.00
Low 0.19 1 Week -0.01 -5.00
Close 0.19 1 Month 0.00 0.00
Volume 6489318 1 Year -78.71 -99.76
52 Week High 85.40 | 52 Week Low 0.13
 
ST Sweden Most Active Stocks
TANGI 0.00 %
FING-B 0.08 0.00%
SBB-B 4.00 1.78%
LUNE 21.97 6.65%
SNM 0.88 2.33%
DIABIO 0.03 0.00%
WYLD 0.02 0.00%
NIBE-B 45.75 1.87%
HDW-B 0.00 %
EURA 0.01 0.00%
 
ST Sweden Top Gainers Stocks
KOPY 0.10 150.00%
SPIFF 0.04 33.33%
STAR-A 0.26 30.00%
LCLEAN 3.20 25.49%
QIIWI 3.10 22.05%
APTR 0.23 21.05%
FLUI 0.06 20.00%
CLS-B 4.50 19.05%
SIVE 2.24 16.06%
SIVE 2.24 16.06%
 
ST Sweden Top Losers Stocks
ALLR 1.55 -26.54%
ASAP 0.03 -25.00%
ASAP 0.03 -25.00%
ASAP 0.03 -25.00%
LOHILO 1.58 -18.56%
ADDV-A 9.82 -18.17%
PHARM 0.56 -16.42%
PHARM 0.56 -16.42%
ONCOZ 3.50 -13.37%
SCOL 0.07 -12.50%
 
 
XBRANE
Daily Charts
XBRANE
Intraday Charts
Whats New @
Bazaartrend
XBRANE
Free Analysis
 
XBRANE Important Levels Intraday
RESISTANCE0.21
RESISTANCE0.20
RESISTANCE0.20
RESISTANCE0.20
SUPPORT0.18
SUPPORT0.18
SUPPORT0.18
SUPPORT0.17
 
XBRANE Forecast November 2024
4th UP Forecast82.18
3rd UP Forecast55.89
2nd UP Forecast39.63
1st UP Forecast23.38
1st DOWN Forecast-23
2nd DOWN Forecast-39.25
3rd DOWN Forecast-55.51
4th DOWN Forecast-81.8
 
XBRANE Weekly Forecast
4th UP Forecast26.20
3rd UP Forecast17.86
2nd UP Forecast12.70
1st UP Forecast7.55
1st DOWN Forecast-7.17
2nd DOWN Forecast-12.32
3rd DOWN Forecast-17.48
4th DOWN Forecast-25.82
 
XBRANE Forecast2024
4th UP Forecast171.64
3rd UP Forecast116.65
2nd UP Forecast82.67
1st UP Forecast48.68
1st DOWN Forecast-48.3
2nd DOWN Forecast-82.29
3rd DOWN Forecast-116.27
4th DOWN Forecast-171.26
 
 
XBRANE Other Details
Segment EQ
Market Capital 3160035328.00
Sector Healthcare
Industry Biotechnology
Offical website >
 
XBRANE Address
XBRANE
 
XBRANE Latest News
 
Your Comments and Response on Xbrane Biopharma AB (publ)
 
XBRANE Business Profile
Xbrane Biopharma AB (publ), a biotechnology company, develops, manufactures, and sells biosimilars. The company is developing Xlucane, a ranibizumab biosimilar that is in Phase III clinical trials used for the treatment of wet age-related macular degeneration, diabetic macular edema, diabetic related retinopathy, and retinal vein occlusion. Its pre-clinical phase products include Xcimzane for rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis and crohn diseases; Xoncane for acute lymphocytic leukemia; Spherotide for prostate cancer, breast cancer, endometriosis, and myoma; and Xdivane for melanoma, lung, head and throat, bladder, and urinary tract cancer, as well as for renal cell carcinoma. The company has a strategic biosimilar development partnership with STADA Arzneimittel AG to evaluate development and commercialization collaborations around its Xcimzane and Xdivane preclinical biosimilars. Xbrane Biopharma AB (publ) was founded in 2008 and is headquartered in Solna, Sweden. Address: Retzius väg 8, Solna, Sweden, 171 65
 
© 2005-2023 BazaarTrend.com All rights reserved.

Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service